This video examines the promise of recent trials studying single-agent immunotherapy as well as ongoing trials testing combinations of immune-checkpoint inhibition.
Anti–CTLA-4 and anti–PD-1 checkpoint inhibitors have both shown promise in the treatment of hepatocellular carcinoma (HCC).
In this video, Ghassan K. Abou-Alfa, MD, of Memorial Sloan Kettering Cancer Center in New York, discusses the promise of recent trials that have studied single-agent immunotherapy and ongoing trials testing combinations of immunotherapies and immune-checkpoint inhibition in different lines of treatment.
Abou-Alfa also highlights the latest results in second-line HCC treatment using the multikinase inhibitor regorafenib, and looks ahead at trials involving c-MET inhibition for patients with HCC.
Sintilimab Combo Shows Modest Efficacy, Safety in HER2– Gastric/GEJ Cancer
February 18th 2024Over half of the patients with HER2-negative gastric or gastroesophageal junction adenocarcinoma achieve a major pathological complete response following treatment with sintilimab plus FLOT in a phase 2 trial.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.
Fruquintinib/Paclitaxel Improves PFS, ORR in Gastric/GEJ Adenocarcinoma
February 7th 2024Findings from the FRUTIGA study support fruquintinib plus paclitaxel as a promising second-line treatment for those with advanced gastric or gastroesophageal junction adenocarcinoma following prior chemotherapy.